PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 288 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Osimertinib April 26, 2021 Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy... October 9, 2020 Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell... September 23, 2025 Study Identifies Hundreds of Potential Targets for Cancer Drugs September 11, 2024 Load more HOT NEWS FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma Five-Year Outcomes with CAR T Cell Therapy EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant...
